These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 17530133)

  • 1. Correlation does not always show a causal relationship.
    Buyukhatipoglu H; Homaei-Shandiz F
    Saudi Med J; 2007 Jun; 28(6):986; author reply 986. PubMed ID: 17530133
    [No Abstract]   [Full Text] [Related]  

  • 2. [Interview with private lecturer Dr. med. Nadia Harbeck, Munich. Prognostic markers guide therapy (interview by Jochen Aumiller)].
    Harbeck N
    MMW Fortschr Med; 2003 Jan; 145(3-4):8, 10. PubMed ID: 12619225
    [No Abstract]   [Full Text] [Related]  

  • 3. [Biological features of breast cancer in patients under 35].
    Damenia AO; Turkevich EA; Semiglazov VF; Kochetova IA; Gurbanov SS; Bit-Sava EM; Efimenko AV
    Vopr Onkol; 2007; 53(6):674-6. PubMed ID: 18416136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Occult multicentric breast cancer].
    Vtorushin SV; Zab'ialova MV; Glushchenko SA; Perel'muter VM; Slonimskaia EM
    Vopr Onkol; 2009; 55(1):38-41. PubMed ID: 19435197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [erbB2 as a prognostic factor of breast cancers].
    Nishimura R; Nagao K; Miyayama H
    Nihon Rinsho; 2000 Apr; 58 Suppl():407-12. PubMed ID: 11026025
    [No Abstract]   [Full Text] [Related]  

  • 6. Human epidermal growth factor receptor 2 testing recommendation.
    Raji A
    J Clin Oncol; 2007 Sep; 25(25):4020-1; author reply 4021-3. PubMed ID: 17761990
    [No Abstract]   [Full Text] [Related]  

  • 7. Is circulating HER-2 more than just a tumor marker?
    Baselga J
    Clin Cancer Res; 2001 Sep; 7(9):2605-7. PubMed ID: 11555569
    [No Abstract]   [Full Text] [Related]  

  • 8. Human epidermal growth factor receptor 2 testing in breast cancer.
    Vang Nielsen K; Jørgensen JT; Schønau A; Øster A
    J Clin Oncol; 2007 Sep; 25(25):4020; author reply 4021-3. PubMed ID: 17761991
    [No Abstract]   [Full Text] [Related]  

  • 9. Breast cancer metastasis: when, where, how?
    Eccles SA; Paon L
    Lancet; 2005 Mar 19-25; 365(9464):1006-7. PubMed ID: 15781080
    [No Abstract]   [Full Text] [Related]  

  • 10. Isolated tumor cells in bone marrow and its relation with known prognostic factors in breast cancer patients.
    Sánchez R; González L; Betancourt L; Rodríguez JJ; Sánchez A; Spinetti D; Parada D; Melone S
    Breast J; 2009; 15(2):212-3. PubMed ID: 19292815
    [No Abstract]   [Full Text] [Related]  

  • 11. [Clinicopathological and biological features of breast cancer in young females and their relationship with prognosis].
    Meng J; Lang RG; Fan Y; Fu L
    Zhonghua Zhong Liu Za Zhi; 2007 Apr; 29(4):284-8. PubMed ID: 17760256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Luminal B breast tumors are not HER2 positive.
    Bhargava R; Dabbs DJ
    Breast Cancer Res; 2008; 10(5):404; author reply 405. PubMed ID: 18831725
    [No Abstract]   [Full Text] [Related]  

  • 13. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.
    Kyndi M; Sørensen FB; Knudsen H; Overgaard M; Nielsen HM; Overgaard J;
    J Clin Oncol; 2008 Mar; 26(9):1419-26. PubMed ID: 18285604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small beginnings: do they matter? The importance of lymphovascular invasion in early breast cancer.
    Chivukula M; Brufsky A; Davidson NE
    J Natl Cancer Inst; 2009 May; 101(10):698-9. PubMed ID: 19436037
    [No Abstract]   [Full Text] [Related]  

  • 15. Anthracyclines in the treatment of HER2-negative breast cancer.
    Paik S; Taniyama Y; Geyer CE
    J Natl Cancer Inst; 2008 Jan; 100(1):2-4. PubMed ID: 18159066
    [No Abstract]   [Full Text] [Related]  

  • 16. Human epidermal growth factor receptor 2 testing in breast cancer: 30% versus 10% cutoff for immunohistochemistry.
    Hameed O; Chhieng D; Adams AL
    J Clin Oncol; 2008 Mar; 26(9):1571. PubMed ID: 18349417
    [No Abstract]   [Full Text] [Related]  

  • 17. Breast cancer.
    Buzdar AU; Hortobagyi GN
    Cancer Chemother Biol Response Modif; 1999; 18():435-69. PubMed ID: 10800497
    [No Abstract]   [Full Text] [Related]  

  • 18. Re: HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials.
    Mehta RS; Schubbert T
    J Natl Cancer Inst; 2008 May; 100(9):680; author reply 680-1. PubMed ID: 18445822
    [No Abstract]   [Full Text] [Related]  

  • 19. The prognostic and predictive values of circulating HER-2/neu extracellular domain in patients with metastatic breast cancer.
    Abu-Khalaf MM; Harris L
    Breast Cancer Res Treat; 2009 Apr; 114(3):513-5. PubMed ID: 18677560
    [No Abstract]   [Full Text] [Related]  

  • 20. Anthracycline therapy may be avoidable in early breast cancer, new studies suggest.
    Tuma R
    J Natl Cancer Inst; 2008 Apr; 100(7):459-61. PubMed ID: 18364497
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.